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Abstract
Background: Although the addition of bevacizumab to 1st line chemotherapy provides a significant survival benefit for 
advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated.
Methods: A literature-based meta-analysis was conducted; Hazard Ratios were extracted from randomized trials for 
primary end-points (Progression Free Survival, PFS, Overall Survival OS). The log of event-based risk ratio were derived 
for secondary endpoints (objective/partial response rate, ORR/PR; severe hypertension, bleeding and proteinuria). 
Absolute differences and the number needed to treat/harm (NNT/NNH) were calculated. A meta-regression analysis 
with clinical predictors and a sensitivity analysis according to the trial phase-design were conducted as well.
Results: Five trials (2,728 pts) were selected. The addition of bevacizumab to 1st line chemotherapy significantly 
increased both PFS (although with significant heterogeneity) and OS over exclusive chemotherapy by 17.1% and 8.6% 
(NNT 6 and 12), regardless of the study setting (non significant interaction between phase II and III). The chance to 
improve PR was significantly increased by 6.5% (NNT 15), with a trend for ORR. The risk of hypertension was significantly 
increased by 6.2% (NNH 16). According to the meta-regression analysis, female gender and rectal primary site were 
significant predictors for PFS benefit.
Conclusions: Notwithstanding all the concerns related to costs and the significant HTN risk, the significant outcome 
improvement provided by bevacizumab in first-line treatment for unselected advanced colorectal cancer patients, 
should be considered when choosing the appropriate up-front therapy.
Introduction
The intuition of the relevant role of newly and aberrantly
formed blood vessels in driving tumor progression has
represented the rational basis to assess the implication of
antiangiogenesis as a therapeutic strategy [1].
Preclinical and early clinical successful evidences about
the effectiveness of the monoclonal antibody anti-VEGF
bevacizumab have been actually confirmed in the large
phase III trial AVF2107 [2], whose impressive results have
led to the approval of bevacizumab for the treatment of
metastatic colorectal cancer (mCRC), in combination
with fluoropyrimidine-based chemotherapy.
The introduction of bevacizumab in the daily practice
has deeply modified the handling of mCRC patients inso-
much as its use has been rapidly and widely adopted as
the standard choice for the first-line treatment. The ini-
tial design of the pivotal trial planned to randomize
patients to receive irinotecan, bolus fluorouracil and leu-
covorin (IFL) plus placebo, IFL plus bevacizumab, or flu-
orouracil and leucovorin (5-FU/LV) plus bevacizumab.
Final analysis revealed that the addition of bevacizumab
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Page 2 of 8to IFL significantly improved OS (primary endpoint, HR:
0.66, p < 0.001), PFS (HR: 0.54, p < 0.001) and RR (44.8%
vs 34.8%, p = 0.004).
The planned analysis comparing patients treated with
5-FU/LV plus bevacizumab with those concurrently
enrolled in the IFL plus placebo group, revealed no signif-
icant differences between arms in terms of OS (HR: 0.82
[0.59-1.15], p = 0.25), PFS (HR: 0.86 [0.60-1.24], p = 0.42)
and RR (49% vs 37%, p = 0.66) [3]. The outcome reported
in the 5-FU/LV plus bevacizumab arm was consistent
with other experiences that explored the use of bevaci-
zumab in combination with 5-FU/LV. In a phase II ran-
domized study, including 104 patients, the combination
of bevacizumab with 5-FU/LV resulted in longer time to
disease progression (TTP, median TTP: 9.0 months [5.8-
10.9] vs 5.2 months [3.5-5.6]) and in better, but not signif-
icantly, RR (40% [24-58] vs 17% [7-23]-34) and OS
(median OS: 21.5 months [17.3-undetermined] vs 13.8
months [9.1-23]) [4]. Similar results were obtained in
another phase II trial, randomizing 209 patients, that
were not optimal candidates for irinotecan-containing
regimens, to receive 5-FU/LV plus or minus bevaci-
zumab. Patients treated with the antiangiogenic obtained
a significantly longer PFS (HR: 0.50 [0.34-0.73], p =
0.0002) and OS, that was the primary endpoint of the
study (HR: 0.79 [0.56-1.10], p = 0.160) [5].
Bevacizumab has been also studied in combination
with oxaliplatin-based regimens in the NO16966 study,
where about 1400 mCRC patients were randomly
assigned according to a 2 × 2 design, to receive either
FOLFOX or XELOX plus bevacizumab or placebo as
first-line treatment [6]. The addition of bevacizumab was
associated with significantly longer PFS (HR: 0.83 [0.72-
0.95], p = 0.0023), that translated into a trend toward bet-
ter OS, though not reaching the statistical significance
(HR: 0.89 [0.76-1.03], p = 0.077). The magnitude of the
effect of bevacizumab seemed less prominent in this
experience, when compared with results achieved in the
AVF2107 study. The frequent discontinuation of the anti-
VEGF together with chemotherapy before disease pro-
gression and not for bevacizumab-related toxicity was
suggested by authors as a possible explanation for such
finding.
On the basis of these results, the choice of bevacizumab
in the routine upfront approach to the treatment of
mCRC is extremely frequent. In fact, it has been demon-
strated relatively safe in association with both irinotecan-
[7] and oxaliplatin-containing regimens [8] and its spe-
cific toxicity profile appears manageable, by applying
appropriate clinical selection criteria [9]. Moreover, dif-
ferently from the anti-EGFR antibodies, the anti-VEGF
may be proposed to all patients, without any molecular
restriction.
However, in spite of its wide use, the magnitude of the
benefit derived by the addition of bevacizumab to con-
ventional cytotoxics is still controversial. The present lit-
erature-based meta-analysis has been conducted with the
aim of quantifying the advantage provided in the daily
practice by the use of bevacizumab-containing regimens
as first-line treatments for mCRC patients.
Materials and methods
The analysis was conducted following 4 steps: definition
of the outcomes (definition of the question the analysis
was designed to answer), definition of the trial selection
criteria, definition of the search strategy, and a detailed
description of the statistical methods used [10,11].
Outcome definition
The combination of Bevacizumab (BEVA) and chemo-
therapy was considered as the experimental arm and
exclusive chemotherapy as the standard comparator.
Analysis was conducted in order to find significant differ-
ences in primary and secondary outcomes, according to
the reported sequence and definitions in the selected tri-
als. Primary outcomes for the magnitude of the benefit
analysis were both Progression Free Survival (PFS, time
between randomization and any progression or death for
any cause) and Overall Survival (OS, time between ran-
domization and any death). Secondary end-points were:
1) ORR (objective response rate), 2) PR (partial response
rate), 3) grade 3-4 hypertension (HTN) rate, 4) grade 3-4
bleeding rate, and 5) grade 3-4 proteinuria rate, if
reported in at least 50% of selected trials. The throm-
boembolic risk was not chosen to be explored because
already reported in literature [12]. A sensitivity analysis
taking into account the trial design setting (i.e. phase II or
phase III) was accomplished.
Search strategy
Deadline for trial publication and/or presentation was
March, 2009. Updates of Randomized Clinical Trials
(RCTs) were gathered through Medline (PubMed: http://
www.ncbi.nlm.nih.gov/PubMed), ASCO (American Soci-
ety of Clinical Oncology, http://www.asco.org), ASCO-GI
(ASCO Gastrointestinal Symposium), ESMO (European
Society for Medical Oncology, http://www.esmo.org), and
FECS (Federation of European Cancer Societies, http://
www.fecs.be) website searches. Key-words used for
searching were: chemotherapy, colorectal cancer, colon,
rectal, bevacizumab, targeted, monoclonal antibodies,
avastin®, review, metanalysis, meta-analysis, pooled anal-
ysis, randomized, phase III, phase II, comprehensive
review, systematic review. In addition to computer
browsing, review and original papers were also scanned
in the reference section to look for missing trials. Fur-
thermore, lectures at major meetings (ASCO, ASCO-GI,
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Page 3 of 8ESMO, and ECCO) having 'chemotherapy and targeted
agents for advanced colorectal cancer' as the topic were
checked. No language restrictions were applied.
Trial identification criteria
All prospective randomized RCTs, either phase II or III,
published in peer-reviewed journals or presented at the
ASCO, ASCO-GI, ECCO, and ESMO meetings until
March 2009, in which previously untreated patients with
advanced/metastatic colorectal cancer were prospec-
tively randomized to receive BEVA plus chemotherapy
(experimental arm) or chemotherapy alone (control arm),
regardless of drug, schedule, dosages, and duration.
Data extraction
Hazard Ratios (HRs) for primary end-points and the
number of events for secondary end-points were
extracted; the last trial's available update was considered
as the original source. All data were reviewed and sepa-
rately computed by five investigators (V.V., F.C., D.G., and
E.B.).
Data synthesis
HRs were extracted from each single trial for primary
end-points, and the log of relative risk ratio (RR) was esti-
mated for secondary endpoints [13], and 95% Confidence
Intervals (CI) were derived [14]. A random-effect model
according to the inverse variance and the Mantel-Haenzel
method was preferred to the fixed, given the known clini-
cal heterogeneity of trials; a Q-statistic heterogeneity test
was used. Absolute benefits for each outcome were calcu-
lated (i.e. absolute benefit = exp {HR/RR×log[control sur-
vival]} - control survival [15]; modified by Parmar et al
[16]). The number of patients needed to treat for one sin-
gle beneficial patient was determined (NNT: 1/[(Absolute
Benefit)/100]) [17]. Results were depicted in all figures as
conventional meta-analysis forest plots; a RR < 1.0 indi-
cates fewer events in the experimental arm. In order to
find possible correlations between outcome effect and
negative prognostic factors (selected among trials'
reported factors, i.e. number of patients with: rectal as
primary site, female gender and adjuvant treatment), a
meta-regression approach was adopted (i.e. regression of
the selected predictor on the Log RR of the correspond-
ing outcome). Calculations were accomplished using the
SPSS software, version 13.0, and the Comprehensive
Meta-Analysis Software, version v. 2.0 (CMA, Biostat,
Englewood, NJ, USA).
Results
Selected trials
Seven trials (3,678 patients) were identified (Figure 1).
One was excluded because of exclusion criteria (i.e. sec-
ond line treatment) [18], another ruled out owing to not
randomized for BEVA assignment [8]. Four RCTs were
evaluable for PFS and OS (2,624 patients, data lacking for
104 patients); with regard to secondary outcomes, 5 trials
were evaluable for ORR and grade 3-4 HTN analysis
(2,728 patients) and 4 trials for grade 3-4 bleeding and
proteinuria (2,570 patients). Four trials (1,336 patients)
reported data for PR determination, one trial was
excluded for lacking data [6]. Trials characteristics are
listed in Table 1.
Combined Analysis
Primary Outcomes: the addition of BEVA to chemother-
apy significantly increased both PFS (although with sig-
Table 1: Trials' characteristics.
Authors Pts Phase Experimental 
Arm
Primary 
End-Point
Secondary 
End-Point
Female (%) Rectal (%) Adjuvant (%)
Hurwitz et al[2] 813 III IFL+Beva OS PFS, ORR, DR, 
QoL
*40% 21% 26%
Hurwitz et al[3] 210 III FU/LV+Beva OS PFS, ORR, DR 39% 29% -
Saltz et al[6] 1,400 III FOLFOX/
XELOX+Beva
PFS PFS, OS, RR, DR, 
TTF
42% 26% 24%
Kabbinavar et al[4] 104 II FU/LV+Beva TTP, RR OS, DR 43% - 19%
Kabbinavar et al[23] 209 II FU/LV+Beva OS PFS, ORR, DR, 
QoL
46% 19% 20%
Pts: patients; IFL: irinotecan, 5-fluorouracil, leucovorin; Beva: bevacizumab; OS: overall survival; PFS: progression-free survival; ORR: overall 
response rate; DR: duration of response; QoL: quality of life; FU: 5-fluorouracil; LV: leucovorin; FOLFOX: 5-fluorouracil, leucovorin, oxaliplatin; 
XELOX: capecitabine, oxaliplatin; TTF: time to treatment failure; TTP: time to progression.
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chemotherapy by 17.1% and 8.6% (Figure 2), respectively,
corresponding to 6 and 12 NNT (Table 2). The benefit is
obtained regardless of study setting, according to the
absence of significant interaction (p = 0.06 and p = 0.93,
respectively) between phase II and phase III pooled
results.
Secondary Outcomes
the addition of BEVA to chemotherapy significantly
increased the chance to achieve PR by 6.5%, which trans-
Figure 1 Outline of the search - Flow diagram. RCTs: randomized clinical trials; Pts: patients; PFS: progression free survival; OS: overall survival; ORR: 
overall response rate; PR: partial response rate; HTN: hypertension.
5 RCTs included in the 
meta-analysis (2,728 pts)
7 Potential RCTs identified
(3,678 pts)
1 RCT excluded because of 
exclusion criteria (second line 
treatment) (577 pts)
4 RCTs evaluable for PFS 
(2,624 pts)
Data not available
for 1 RCT (104 pts)
Primary Outcomes Secondary Outcomes
4 RCTs evaluable for OS 
(2,624 pts)
2 RCTs excluded because of 
exclusion criteria (not randomized)
(373 pts)
5 RCTs evaluable for ORR, G3-4 HTN
(2,728 pts)
4 RCTs evaluable for PR
(1,336 pts)
Data not available
for 1 RCT (1,392 pts)
4 RCTs evaluable for G3-4 Bleeding, G3-4 Proteinuria
(2,570 pts)
Data not available
for 1 RCT (102 pts)
Table 2: Combined efficacy results according to primary and secondary outcomes.
Outcomes Pts (RCTs) HR/RR (95% CI) p-value Het. (p) AD (%) NNT
PFS 2,624 (4) 0.62 (0.48, 0.69) < 0.0001 0.001 17.1 6
OS 2,624 (4) 0.78 (0.66, 0.94) 0.007 0.14 8.6 12
ORR 2,728 (5) 1.16 (0.97, 1.38) 0.085 0.034 - -
PR 1,336 (4) 1.24 (1.06, 1.46) 0.006 0.19 6.5 15
Pts: patients; RCTs: randomized clinical trials; HR: hazard ratio; RR: relative risk; CI: confidence intervals; Het.: heterogeneity; AD: absolute 
difference; NNT: number needed to treat; PFS: progression free survival; OS: overall survival; ORR: overall response rate; PR: partial response 
rate.
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nous trend in favour of BEVA is found for ORR rate as
well (Figure 3). The risk of hypertension is significantly
increased with the addition of BEVA by 6.2%, which cor-
responds to 16 NNH (Table 3). No significant differences
in grade 3-4 bleeding and proteinuria (although a trend
against BEVA) were observed by comparing the two
arms, without heterogeneity (Table 3). According to the
meta-regression analysis, female gender and rectal pri-
mary site were significant predictors for PFS benefit (p =
0.003, p = 0.005, Figure 4).
Discussion
Combinations of conventional cytotoxics plus BEVA as
1st line treatment for mCRC patients are one of the possi-
ble standard options. Given the impressive results of the
phase III AVF2107 trial, it seemed almost clear that a bio-
logic agent able to extend median PFS and median OS by
more than 4 months, with a 44% reduction of the risk of
Figure 2 Combined results according to sensitivity analysis - Primary outcomes. CI: confidence interval; PFS: progression free survival; OS: overall 
survival; BEVA: bevacizumab.
II Kabbinavar JCO 2005OS
II
III Hurwitz NEJM 2004 OS
III Hurwitz JCO 2005 OS
III Saltz JCO 2008 OS
III
Overall
II Kabbinavar JCO 2005PFS
II
III Hurwitz NEJM 2004 PFS
III Hurwitz JCO 2005 PFS
III Saltz JCO 2008 PFS
III
Overall
p-Value
0,000
0,000
0,000
0,415
0,008
0,041
0,000
0,171
0,171
0,000
0,244
0,133
0,021
0,007
0,5 1 2
Group by
Phase
Study name Outcome Hazard ratio and 95% CI
Favours BEVA Favours Control
Table 3: Combined toxicity (Grade 3-4) results.
Outcomes Pts (RCTs) RR (95% CI) p-value Het. (p) AD (%) NNH
HTN 2,728 (5) 4.87 (3.12, 
7.61)
< 0.0001 0.93 6.2 16
Bleeding 2,570 (4) 1.72 (0.96, 
3.07)
0.07 0.52 - -
Proteinuria 2,570 (4) 2.10 (0.64, 
6.84)
0.21 0.56 - -
Pts: patients; RCTs: randomized clinical trials; RR: relative risk; CI: confidence intervals; Het.: heterogeneity; AD: absolute difference; NNH: 
number needed to harm; HTN: hypertension.
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0.001), would have found a wide space in the oncologic
practice, considering also its satisfactory toxicity profile.
However, such exciting results produced by adding BEVA
to the IFL regimen have not been fully confirmed by sub-
sequent trials that tested the addition of the antiangio-
genic to other regimens. In particular, the NO16966
study (oxaliplatin based doublets plus or minus BEVA)
met its primary endpoint of improving PFS for patients
treated with bevacizumab, with a smaller than expected
reduction in the risk of progression of 17% (p = 0.0023),
but this did not translate in a significant advantage in
terms of OS [6]. A plausible explanation for such findings
resides in the discontinuation of BEVA - even indepen-
dently from the occurence of BEVA-related toxicities -
before disease progression much more frequently in this
study, in comparison to the pivotal trial by Hurwitz et al
[6].
Moving from the above reported results it has been
hypothesized that the advantage produced by the addi-
tion of BEVA in first-line may vary depending on the
combination regimen adopted and that it has been more
evident with an almost abandoned regimen (IFL). This
underlines the importance of meta-analyses trying to
estimate the cumulative magnitude of BEVA's effect.
Figure 3 Combined results according to sensitivity analysis - Secondary outcomes. CI: confidence interval; ORR: overall response rate; PR: partial 
response rate; BEVA: bevacizumab.
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the addition of BEVA to first-line chemotherapy regimens
(IFL, FOLFOX, XELOX, 5-FU/LV) would provide a sig-
nificant advantage in terms of both PFS and OS, with an
increase of 17,1% and 8,6% respectively, in comparison to
exclusive chemotherapy.
On the other hand, BEVA does not seem to allow to
achieve an higher rate of response, even if a trend toward
significance (p = 0.085) is reported. Such finding is not
surprising at all, since it is well known that tumoral
shrinkage may represent an inappropriate parameter, in
order to appreciate the real benefit provided by antian-
giogenic drugs. Such agents are able to exert a clinically
meaningful disease control, that translates into a signifi-
cant improvement of survival, even though not determin-
ing an impressive tumor downsizing. This observation
acquires a crucial importance in the choice of the best
biologic agent (bevacizumab vs cetuximab) to be com-
bined with upfront chemotherapy, especially in patients
with potentially resectable disease. At the same, it should
be considered that anti-EGFRs are not active in KRAS
mutant patients while the only data from a phase III ran-
dom study looking at response rate with BEVA in a sub-
group of KRAS wild-type patients demonstrated a
response rate of 60% for IFL plus the anti-VEGF [19].
This does not differ too much from the 59.3% obtained in
the CRYSTAL trial adding cetuximab to FOLFIRI for
KRAS wild-type patients [20]. Only head-to-head ongo-
ing phase III random trials will address this question.
As it regards the toxicity profile, it is confirmed the rel-
atively safe use of BEVA, as already suggested by BEAT
[9] and BRiTE registers [21], that included about 4000
patients, treated with the anti-VEGF in the clinical prac-
tice. In the present metanalysis the addition of BEVA sig-
nificantly increased the risk of hypertension by 6.2%,
while no significant differences in grade 3-4 bleeding and
proteinuria were observed.
According to the our meta-regression analysis, female
gender and rectal primary site were significant predictors
for PFS benefit: we do not have any biological or clinical
explanation for such unexpected finding. Future studies
should be conducted for confirming these results and
therefore to drive reliable hypothesis.
According to our results, the addition of BEVA to first-
line chemotherapy seems to improve treatment's efficacy
in an overall population, selected on the basis of the
inclusion criteria of gathered trials, that tended to
exclude patients prone to experience BEVA-related toxic-
ities because of their cardiovascular comorbidities or
bleeding diatheses. Despite that, from a clinical perspec-
tive, the identification of molecular predictors of benefit
from the antiangiogenic drug could be extremely useful
to refine patients' selection and to improve the cost-effec-
tiveness ratio [22]. In fact, on the one hand, this step for-
ward could allow to avoid the harmful cost of
unnecessary and potentially life-threatening toxicities to
patients with poor chances to achieve benefit from the
anti-VEGF antibody. On the other hand, the magnitude
of the advantage provided by the addition of BEVA to
chemotherapy would be certainly more extensive in a
better selected population [22].
The above reported observations acquire an even more
crucial importance, considering the current possibility to
administer both the anti-VEGF bevacizumab and the
anti-EGFR cetuximab - for which only patients with
KRAS wild-type disease are candidate - in the first-line
approach to mCRC, but not at the same time. The detri-
mental effect of the double inhibition binds the oncolo-
gist to face an unavoidable point of decision for the
handling of KRAS wild type patients and only the avail-
ability of new markers of benefit may help to define the
best strategy for each patient.
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